Abstract

It is generally accepted that radiotherapy must target clonogenic cells, i.e., those cells in a tumour that have self-renewing potential. Focussing on isolated clonogenic cells, however, may lead to an underestimate or even to an outright neglect of the importance of biological mechanisms that regulate tumour cell sensitivity to radiation. We develop a new statistical and experimental approach to quantify the effects of radiation on cell populations as a whole. In our experiments, we change the proximity relationships of the cells by culturing them in wells with different shapes, and we find that the radiosensitivity of T47D human breast carcinoma cells in tight clusters is different from that of isolated cells. Molecular analyses show that T47D cells express a Syncytin-1 homologous protein (SyHP). We observe that SyHP translocates to the external surface of the plasma membrane of cells killed by radiation treatment. The data support the fundamental role of SyHP in the formation of intercellular cytoplasmic bridges and in the enhanced radioresistance of surviving cells. We conclude that complex and unexpected biological mechanisms of tumour radioresistance take place at the cell population level. These mechanisms may significantly bias our estimates of the radiosensitivity of breast carcinomas in vivo and thereby affect treatment plans, and they call for further investigations.

Highlights

  • Breast cancer is the most common cancer in women worldwide, with 5-year survival rates that vary from 80% in developed countries to less than 40% in low-income countries [1]

  • Post-surgical adjuvant radiotherapy has been demonstrated to be effective in the control of local and regional microscopic residual disease and to reduce breast cancer-specific mortality, and high-risk patients in the post-mastectomy settings benefit from radiotherapy [2,3]

  • Cell populations growing in V-bottom wells showed a higher probability to survive 8 Gy treatment with respect to those growing in F-bottom wells

Read more

Summary

Introduction

Breast cancer is the most common cancer in women worldwide, with 5-year survival rates that vary from 80% in developed countries to less than 40% in low-income countries [1]. Post-surgical adjuvant radiotherapy has been demonstrated to be effective in the control of local and regional microscopic residual disease and to reduce breast cancer-specific mortality, and high-risk patients in the post-mastectomy settings benefit from radiotherapy [2,3].

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.